



HOUSE COMMITTEE ON APPROPRIATIONS

FISCAL NOTE

HOUSE BILL NO. 427

PRINTERS NO. 2194

PRIME SPONSOR: Benninghoff

COST / (SAVINGS)

FUND	FY 2018/19	FY 2019/20
General Fund	\$0	See Fiscal Impact

SUMMARY: House Bill 427, Printer's Number 2194, establishes the Fair Access to Cancer Treatment Act. This legislation is effective in 60 days.

ANALYSIS: With this legislation, health insurance policies that cover treatments for stage four metastatic cancers will not be able to limit or exclude innovative drugs for those patients if the drugs have been approved by the U.S. Food and Drug Administration for this indication and are consistent with best practices for stage four, metastatic cancer treatment or associated conditions. Specifically, patients will not have to first provide that they failed to respond to a different drug or drugs before they are provided coverage.

For health insurance policies for which rates or forms are required to be filed with the federal government or the Insurance Department, this Act shall apply to any policy for which the form or rate is first filed on or after 180 days after the effective date of this act.

For health insurance policies for which neither rates or forms are required to be filed, this Act shall apply to any policy issued or renewed on or after 180 days after the effective date of this act.

FISCAL IMPACT: According to the American Cancer Society, 79,890 Pennsylvanians (0.6% of the state's population) are projected to be diagnosed with cancer in 2019. An unknown percentage of cancer diagnoses will progress to stage IV and these individuals could potentially choose innovative drugs without progressing through different drug treatment regimens. The difference in the cost of these treatment regimens cannot be calculated, therefore enactment of this legislation would have an unknown impact on Commonwealth funds.

PREPARED BY: Ann Bertolino
House Appropriations Committee (R)

DATE: June 24, 2019

Estimates are calculated using the best information available. Actual costs and revenue impact incurred may vary from estimates.